{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:46:53Z","timestamp":1792277213943,"version":"4.4.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic mastocytosis, patients experienced rapid and durable disease control. The overall response rate was 72%, and 56% of patients experienced a complete or partial response. No patients discontinued treatment due to adverse events, most of which were mild to moderate in nature.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2017-177","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T01:25:52Z","timestamp":1513128352000},"page":"133-133","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid Responses to Avapritinib (BLU-285) in Mastocytosis"],"prefix":"10.1158","volume":"8","member":"1086","published-online":{"date-parts":[[2018,2,4]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/2\/133\/1809595\/133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/8\/2\/133\/1809595\/133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:03:02Z","timestamp":1654563782000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/8\/2\/133\/6315\/Rapid-Responses-to-Avapritinib-BLU-285-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,4]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2017-177","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]}}}